Nolvadex Cas No.54965-24-1

SKU: WGP-54965-24-1

CAS No.: 54965-24-1
MF: C32H37NO8
MW: 563.64
  • Description
  • Additional information

Description

Product Name: Tamoxifen citrate
Synonyms: (Z)-[2-[4-(1,2-diphenylbut-1-enyl)phenoxy]ethyl]dimethylammonium dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate;TAMOXIPHEN;Ethanamine, 2-4-(1Z)-1,2-diphenyl-1-butenylphenoxy-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);TAMOXIFENCITRATE,USP;TAMOXIFEN CITRATE ANTI-ESTROGEN, PROTEI;TomixipheneCitrate;(Z)-1-(4-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene Citrate;(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, citrate (1:1)
CAS: 54965-24-1
MF: C32H37NO8
MW: 563.64
EINECS: 259-415-2

 

Application:

Long term use of Tamoxifen as prophylaxis is recommended and found useful with decrease in recurrence rate of breast cancer. The risk-lowering effect of Tamoxifen appears to persist for at least 10 years, yet most side effects of Tamoxifen do not continue after the 5-year treatment period. Thus the long-term treatment with Tamoxifen is appreciated[4]. Tamoxifen has been the adjuvant therapy of choice for postmenopausal, node-positive, and estrogen or progesterone receptor positive women since the mid-1980s, and for postmenopausal, node-negative, and estrogen or progesterone receptor-positive women since the early 1990s. It is also being used in many cases of node-negative and receptor-positive premenopausal women. A high proportion (40-60%) of all women who undergo potentially curative surgery for breast cancer now receive adjuvant Tamoxifen therapy for a period of 2 to 5 years. It was first approved for pharmaceutical use in the United Kingdom in 1973 and in the United States in 1977; Tamoxifen is presently registered in 97 countries. Tamoxifen use has been estimated at more than 7 million patient/years. The usual dose in the United States and the United Kingdom is 20 mg/day for 1 to 2 years whereas in continental Europe, usual doses are 30 to 40 mg/day[5].
Tamoxifen is used for the treatment of invasive breast cancer in men and women, the most common type of breast cancer, following surgery and/or radiation and for preventing invasive breast cancer in women at high risk for developing it. Tamoxifen also is used for the treatment of women following surgery and radiation for a less common type of breast cancer called ductal carcinoma in situ (DCIS or Intraductal Carcinoma). Women who have had DCIS are at high risk for developing invasive breast cancer at a later date, and tamoxifen prevents development of the invasive cancer in almost half of the women during the first five years of treatment. Occasionally, tamoxifen is used to stimulate ovulation.

Additional information

Color

White

Form

Powder

You may also like…

Reviews

There are no reviews yet.

Be the first to review “Nolvadex Cas No.54965-24-1”